At the Life Sciences Greenhouse of Central Pennsylvania (LSGPA), we are committed to advancing the life sciences and improving the lives of Pennsylvanians through innovations in healthcare and enhanced economic opportunity. Since 2002, we have been actively funding healthcare technology companies in their very earliest stages, from emerging entities and companies seeking to expand or relocate, to university-based researchers or technology development groups. In addition to early stage funding, we also provide connections to other investors, strategic partners, and resources, as well as consulting expertise that enables the transition from discovery to commercialization and drives companies forward.
MacuLogix Introduces the AdaptDx Pro Guided by Theiahttp://ow.ly/ boXb30qagsc
Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. http://ow.ly/ SOb030pvIfm
INDIGO Biosciences Welcomes New Member to Board of Directors. https:// indigobioscience s.com/ indigo-bioscienc es-welcomes-new -member-to-boar d-of-directors/
Micro Interventional Devices honored by Philadelphia Alliance for Capital and Technologies, better known as PACT, at its 2019 Enterprise Awards event. http://ow.ly/ u2xc50ujWLH
MacuLogix Raises $38.7 Million in Series D Financing Led by Vivo Capital. Investment will accelerate domestic and international sales through expansion of workforce and company infrastructure. http://ow.ly/ O7Bh30nVHAc
MacuLogix® Relocates to Larger Headquarters in Harrisburg, Pennsylvania to Accommodate Rapid Growth https://t.co/I5HartKpel
Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ. (https://t.co/zEeaY4yv1s)
THE LIFE SCIENCES GREENHOUSE OF CENTRAL PA PUMPED NEARLY $2.5 MILLION INTO CENTRAL PENNSYLVANIA STARTUPS IN 2018.… https://t.co/B1Jf5YyUps
Saladax Submits for FDA Review a Rapid Blood Test for Levels of Risperidone https://t.co/4acAXiGAaw
Saladax Signs Licensing Agreement with Janssen for Antipsychotic Drug Testing Patents https://t.co/LINVnai8PO